Ginkgo Bioworks Holdings Valuation

Is DNA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DNA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DNA *'s fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DNA *'s fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DNA *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for DNA *. This is calculated by dividing DNA *'s market cap by their current preferred multiple.
What is DNA *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$450.69m

DNA * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	-0.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does DNA *'s PS Ratio compare to its peers?

The above table shows the PS ratio for DNA * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.9x
CYDSASA A Cydsa. de	0.6x	9.2%	Mex$8.3b
ALPEK A ALPEK. de	0.2x	6.4%	Mex$26.8b
ORBIA * Orbia Advance Corporation. de	0.3x	4.8%	Mex$38.2b
MFRISCO A-1 Minera Frisco. de	2.5x	n/a	Mex$21.2b
DNA * Ginkgo Bioworks Holdings	2.4x	12.7%	Mex$450.7m

Price-To-Sales vs Peers: DNA * is expensive based on its Price-To-Sales Ratio (2.4x) compared to the peer average (0.9x).

Price to Earnings Ratio vs Industry

How does DNA *'s PE Ratio compare vs other companies in the South American Chemicals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	52.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	52.0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: DNA * is expensive based on its Price-To-Sales Ratio (2.4x) compared to the Global Chemicals industry average (1.3x).

Price to Sales Ratio vs Fair Ratio

What is DNA *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DNA * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate DNA *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.